These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 24607048)
21. Psychosocial variables are related to future exacerbation risk and perinatal outcomes in pregnant women with asthma. Powell H; McCaffery K; Murphy VE; Hensley MJ; Clifton VL; Giles W; Gibson PG J Asthma; 2013 May; 50(4):383-9. PubMed ID: 23368420 [TBL] [Abstract][Full Text] [Related]
22. Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma. Özgür ES; Özge C; Ïlvan A; Naycı SA J Asthma; 2013 Aug; 50(6):687-94. PubMed ID: 23557459 [TBL] [Abstract][Full Text] [Related]
23. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy. Dal Negro RW; Tognella S; Pradelli L J Asthma; 2012 Oct; 49(8):843-8. PubMed ID: 22954018 [TBL] [Abstract][Full Text] [Related]
24. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. National Asthma Education and Prevention Program J Allergy Clin Immunol; 2007 Nov; 120(5 Suppl):S94-138. PubMed ID: 17983880 [TBL] [Abstract][Full Text] [Related]
25. Ratio of controller to total asthma medications: determinants of the measure. Broder MS; Gutierrez B; Chang E; Meddis D; Schatz M Am J Manag Care; 2010 Mar; 16(3):170-8. PubMed ID: 20225912 [TBL] [Abstract][Full Text] [Related]
26. Overall asthma control: the relationship between current control and future risk. Bateman ED; Reddel HK; Eriksson G; Peterson S; Ostlund O; Sears MR; Jenkins C; Humbert M; Buhl R; Harrison TW; Quirce S; O'Byrne PM J Allergy Clin Immunol; 2010 Mar; 125(3):600-8, 608.e1-608.e6. PubMed ID: 20153029 [TBL] [Abstract][Full Text] [Related]
27. Health-related quality of life and future health care utilization for asthma. Eisner MD; Ackerson LM; Chi F; Kalkbrenner A; Buchner D; Mendoza G; Lieu T Ann Allergy Asthma Immunol; 2002 Jul; 89(1):46-55. PubMed ID: 12141720 [TBL] [Abstract][Full Text] [Related]
28. A computerized asthma-specific quality of life: a novel tool for reflecting asthma control and predicting exacerbation. Kim MA; Ye YM; Park JW; Lee JH; Lee SK; Kim CW; Jung KS; Kim JH; Yoo HS; Kim SH; Shin YS; Nahm DH; Park HS; Int Arch Allergy Immunol; 2014; 163(1):36-42. PubMed ID: 24247849 [TBL] [Abstract][Full Text] [Related]
29. Asthma Exacerbations and Triggers in Children in TENOR: Impact on Quality of Life. Chipps BE; Haselkorn T; Rosén K; Mink DR; Trzaskoma BL; Luskin AT J Allergy Clin Immunol Pract; 2018; 6(1):169-176.e2. PubMed ID: 28803186 [TBL] [Abstract][Full Text] [Related]
30. Associations between fluctuations in lung function and asthma control in two populations with differing asthma severity. Thamrin C; Nydegger R; Stern G; Chanez P; Wenzel SE; Watt RA; FitzPatrick S; Taylor DR; Frey U Thorax; 2011 Dec; 66(12):1036-42. PubMed ID: 21602542 [TBL] [Abstract][Full Text] [Related]
31. Moderate symptom-based exacerbations as predictors of severe claims-based exacerbations in asthma. Lane SJ; Petersen H; Seltzer JM; Blanchette CM; Navaratnam P; Allen-Ramey F; Fuhlbrigge A J Asthma; 2013 Aug; 50(6):642-8. PubMed ID: 23514102 [TBL] [Abstract][Full Text] [Related]
32. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Peters SP; Ferguson G; Deniz Y; Reisner C Respir Med; 2006 Jul; 100(7):1139-51. PubMed ID: 16713224 [TBL] [Abstract][Full Text] [Related]
34. TENOR risk score predicts healthcare in adults with severe or difficult-to-treat asthma. Miller MK; Lee JH; Blanc PD; Pasta DJ; Gujrathi S; Barron H; Wenzel SE; Weiss ST; Eur Respir J; 2006 Dec; 28(6):1145-55. PubMed ID: 16870656 [TBL] [Abstract][Full Text] [Related]
35. Relationship of asthma control to asthma exacerbations using surrogate markers within a managed care database. Schatz M; Zeiger RS; Yang SJ; Chen W; Crawford WW; Sajjan SG; Allen-Ramey F Am J Manag Care; 2010 May; 16(5):327-33. PubMed ID: 20469953 [TBL] [Abstract][Full Text] [Related]
36. Process quality measures and asthma exacerbations in the medicaid population. Yong PL; Werner RM J Allergy Clin Immunol; 2009 Nov; 124(5):961-6. PubMed ID: 19748660 [TBL] [Abstract][Full Text] [Related]
37. Effect of combination fluticasone propionate and salmeterol or inhaled corticosteroids on asthma-related outcomes in a Medicare-eligible population. Stanford RH; Blanchette CM; Roberts MH; Petersen H; Fuhlbrigge AL Am J Geriatr Pharmacother; 2012 Dec; 10(6):343-51. PubMed ID: 23083688 [TBL] [Abstract][Full Text] [Related]
38. Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma. Sullivan SD; Rasouliyan L; Russo PA; Kamath T; Chipps BE; Allergy; 2007 Feb; 62(2):126-33. PubMed ID: 17298420 [TBL] [Abstract][Full Text] [Related]
39. Changes in total IgE plasma concentration measured at the third month during anti-IgE treatment predict future exacerbation rates in difficult-to-treat atopic asthma: a pilot study. Dal Negro RW; Guerriero M; Micheletto C; Tognella S; Visconti M J Asthma; 2011 Jun; 48(5):437-41. PubMed ID: 21599560 [TBL] [Abstract][Full Text] [Related]
40. A randomized controlled evaluation of specialist nurse education following accident and emergency department attendance for acute asthma. Levy ML; Robb M; Allen J; Doherty C; Bland JM; Winter RJ Respir Med; 2000 Sep; 94(9):900-8. PubMed ID: 11001084 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]